Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
On my outpatient clinical rotations last year, I saw ample management of heart disease and smoking cessation counseling. I also saw the annual physicals and checkups. But what surprised me was how many patients were on medications that were just now be…
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! In this episode, we sit down with Caissa Troutman, an obesity medicine and family physician, to delve into the pervasive stigma and shame associated with obesity and perim…
Imagine snuggling up in bed and drifting off into dreamland after a long day. Did you know that those precious hours of sleep could be more than just time for rest? Let’s explore the interesting connection between sleep and weight loss and why ge…
Recently, media outlets and social media influencers have been on fire with stories about new “miracle” obesity drugs that promise a quick fix for people wanting to lose weight. Lost in this chatter are the life stories of millions of Ameri…
I was in rheumatology private practice for just under four years as my first few years out of fellowship. During that time, too many of my patients were coming with obesity complicating a facet of their rheumatic disease. The most common example might …
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace…
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace pres…
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having t…
